The State of Biotech 2024

The world of biotechnology is in the midst of a wave of exciting research and clinical advances—from artificial intelligence-based drug discovery to cell and gene therapy, to precision genome editing and other newer technologies. These advances are driving new therapies for patients and fueling recoveries for the markets that generate capital for the industry, from the venture capital that powers private startups, to the initial public offerings of more mature companies.

In GEN’s flagship virtual event, The State of Biotech—sponsored exclusively by Cytiva—we proudly host an outstanding group of research and business leaders from industry and academia to discuss the latest research developments, innovations, disruptive technologies and regulatory changes that will spur biotech forward to bigger and better things, for patients around the world.

Please join us on September 11 for an exciting program featuring:

• An opening keynote with David Altshuler, MD, PhD, Executive VP and Chief Scientific Officer of Vertex Pharmaceuticals
• A keynote presentation with John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO)
• Back by popular demand, the co-hosts of the popular Biotech Hangout podcast—Daphne Zohar, Brad Loncar, and Chris Garabedian—review the highs and lows of the biotech space
• A timely discussion on the state of artificial intelligence in biotech with industry experts from Google, NVIDIA and Recursion
• A conversation with Tim Harris, author of the new book In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology—a crackling memoir chronicling the history of biotech
• Building a path for CRISPR therapies with Brad Ringeisen, PhD (IGI) and Sadik Kassim, PhD (Danaher)
• Parallel breakout sessions hosted by Cytiva